Short answer
Septerna, Inc. (SEPN) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Reg FD disclosure furnished under Items 7.01 and Exhibits 99.1–99.2.
Septerna, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure furnished under Items 7.01 and Exhibits 99.1–99.2
- Materials excluded from Exchange Act Section 18 liability
- Exhibits not incorporated by reference into other filings unless expressly stated
Item EX-99.1 · Exhibit EX-99.2
- SEP-479 entered Phase 1, marking Septerna’s first clinical test of its oral PTH1R agonist for hypoparathyroidism
- Trial may enroll up to 150 healthy adults, assessing safety, tolerability, pharmacokinetics and pharmacodynamics
- Once-daily oral dosing targets an unmet need versus frequent calcium supplements or daily PTH injections
- Phase 1 data expected in late 2026 or early 2027, creating a key clinical catalyst
- Preclinical efficacy remains unvalidated clinically, with safety and biomarker results representing primary near-term risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Septerna, Inc. 8-K filings
Get the next SEPN 8-K as it lands
Follow SEPN for push alerts, or ask the research agent what this filing means.